As part of our commitment to be a leader in women’s health care, we continually conduct clinical research studies to advance treatment methods and to identify the most effective means to care for patients.We want to be on the cutting edge of medicine and contribute, first-hand, to benefit not only Rosemark patients but also patients around the world.
Rosemark Clinical Research is now enrolling participants in investigational drug studies in the following areas:
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects for acute yeast infections.
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent
yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
Several properties of VT-1161 suggest it might be a safer and more effective treatment
of RVVC than other oral antifungal medications.
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.